Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/LO/1211	207428	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics,Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera? in Anti TNFInadequate Responder Patients with Moderate to Seve	Range Agreed	1	2	Date Agreed	01/08/2018	0	20/07/2018	0	Recruitment Finished
2	18/NW/0412	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula for children over 1 year of age	Range Agreed	1	7	Date Agreed	31/08/2018	5	31/08/2018	5	Recruitment Finished
3	13/NW/0003	117310	AKPA 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Severe Sepsis and Coagulopathy	Range Agreed	1	6	Date Agreed	30/09/2018	3	13/09/2018	3	Recruitment Finished
4	13/NI/0123	135437	MILES - UK: Post marketing, multicenter, single arm, obervational clinical registry to evaluate safety and efficacy of BioMime sirolimus eluting stent system in all comers real world population with coronary artery stenosis in United Kingdom	Number Agreed	10	10	Date Agreed	31/07/2018	25	31/08/2018	25	Recruitment Finished
5	15/LO/1079	177212	A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem? Therapy in Subjects with Acute RespiratoryDistress Syndrome	Range Agreed	2	3	Date Agreed	31/03/2018	2	19/09/2018	4	Recruitment Finished
6	17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studyto Evaluate the Safety and Efficacy of CCX168 (Avacopan) inPatients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab orCyclophosph	Number Agreed	2	2	Date Agreed	31/12/2018	2	04/07/2018	2	Recruitment Finished
7	17/EM/0405	223871	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Range Agreed	1	10	Date Agreed	30/09/2018	3	21/09/2018	3	Recruitment Finished
8	16/NW/0089	165834	IronWood	Number Agreed	40	40	Not Available / Not Agreed			01/08/2018	42	Recruitment Finished
9	18/NE/0103	241640	A Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapy in subjects with cystic fibrosis who are homozygous for the F508del Mutation (F/F)	Range Agreed	1	2	Date Agreed	31/01/2018	0	21/07/2018	2	Recruitment Finished
10	17/NW/0635	228844	A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough	Number Agreed	10	10	Date Agreed	08/10/2018	0	28/09/2018	0	Withdrawn By Sponsor

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
11	18/NE/0104	241180	A phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-659 combination therapyin subjects with cystic fibrosis who are heterozygous for the F508del mutation and a minimal function mutation (F/MF)	Number Agreed	2	2	Date Agreed	31/08/2018	0	21/07/2018	3	Recruitment Finished
12	18/LO/0068	235852	Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)	Number Agreed	1	1	Date Agreed	31/10/2019	0	10/10/2018	0	Withdrawn By Sponsor
13	18/NE/0200	244356	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Range Agreed	1	3	Date Agreed	31/10/2018	3	31/10/2018	3	Recruitment Finished
14	15/NW/0769	171345	CTP005 - A Feasibility study of the Use of ReCell? Autologous Cell Harvesting Device for Diabetic Foot Ulcers	Range Agreed	6	21	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished
15	15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	2	2	Date Agreed	31/10/2018	2	08/10/2018	2	Recruitment Finished
16	17/YH/0313	232939	RelAxCough	Range Agreed	10	15	Date Agreed	30/11/2018	12	29/12/2018	12	Recruitment Finished
17	17/EM/0060	215678	Protocol I1F-MC-RHBY. A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in P	Number Agreed	2	2	Date Agreed	28/09/2018	2	28/09/2018	2	Recruitment Finished
18	17/EM/0324	225749	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotidecapsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatinreceptor ligands (SRL	Range Agreed	1	2	Date Agreed	31/08/2018	2	01/10/2018	2	Recruitment Finished
19	18/SC/0098	241440	A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens	Number Agreed	2	2	Date Agreed	28/02/2019	2	30/08/2018	2	Recruitment Finished
20	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib oncardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): Thedal-GenE trial?.	Number Agreed	6	6	Date Agreed	01/11/2018	13	01/11/2018	13	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
21	15/NW/0142	164099	Adapt Response	Number Agreed	20	20	Date Agreed	31/01/2019	10	31/01/2019	10	Recruitment Finished
22	15/WM/0453	172946	An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with ER positive HER-2 negative Primary Breast Cancer	Number Agreed	1	1	Date Agreed	11/01/2019	0	11/01/2019	26	Recruitment Finished
23	18/LO/0782	245936	A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Na?ve Participants with Neovascular Age-Related Macular Degeneration (AMD)	Range Agreed	1	4	Date Agreed	01/03/2019	1	01/03/2019	1	Recruitment Finished
24	18/EM/0228	248988	A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients	Number Agreed	3	3	Date Agreed	11/03/2019	1	12/03/2019	1	Recruitment Finished
25	16/LO/1012	205250	A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind,Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy ofTolvaptan followed by a Two Year Open-label Extension in Children and AdolescentSubjects with	Range Agreed	1	5	Date Agreed	18/10/2020	9	15/11/2018	9	Recruitment Finished
26	16/NE/0255	200900	External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone? in Leber?s Hereditary Optic Neuropathy (LHON)	Range Agreed	1	3	Date Agreed	28/02/2019	5	08/03/2019	7	Recruitment Finished
27	17/LO/0113	219400	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally toPatients With Sickle Cell Disease	Range Agreed	1	6	Date Agreed	30/06/2018	2	19/03/2019	2	Recruitment Finished
28	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety,tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a12-week treatment pe	Number Agreed	4	4	Date Agreed	18/12/2018	1	07/02/2019	1	Recruitment Finished
29	16/LO/0878	201070	Prospective, multi-centre study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for haemodialysis.	Range Agreed	15	20	Date Agreed	31/12/2019	13	06/03/2019	13	Recruitment Finished
30	13/LO/1891	138192	More Response on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP)	Number Agreed	10	10	Date Agreed	01/09/2020	18	16/08/2018	18	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
31	15/EM/0543	176792	A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk Fi	Range Agreed	1	5	Date Agreed	30/11/2018	1	11/03/2019	1	Withdrawn By Host
32	15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	1	4	Date Agreed	30/06/2019	4	17/06/2019	4	Recruitment Finished
33	16/SC/0615	210762	A Phase 4 open-label randomized controlled study COmparing the effectiveness of adalimumab iNTROduction andmethotrexate dose escaLation in subjects with Psoriatic Arthritis (CONTROL)	Range Agreed	1	5	Date Agreed	15/10/2018	11	07/05/2019	12	Recruitment Finished
34	16/WM/0436	208631	A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma	Range Agreed	1	1	Date Agreed	05/02/2019	0	03/01/2019	0	Recruitment Finished
35	16/WM/0511	218115	A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elec	Number Agreed	1	1	Date Agreed	31/12/2019	0	23/04/2019	0	Recruitment Finished
36	17/EE/0474	229785	An Open-Label, Randomized, Multi-Center, Parallel Group, Two-Arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-Risk Pediatric Allogenei	Range Agreed	1	4	Date Agreed	31/05/2019	3	09/05/2019	3	Withdrawn By Sponsor
37	17/EM/0063	213979	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remi	Range Agreed	1	3	Date Agreed	31/03/2019	0	10/04/2019	0	Withdrawn By Sponsor
38	17/EM/0404	223875	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjuncti	Range Agreed	1	10	Date Agreed	31/12/2020	2	03/05/2019	2	Withdrawn By Sponsor
39	17/LO/0041	219676	CardioMEMS Heart Failure System "Outside US" Post-Approval Study	Range Agreed	1	10	Date Agreed	01/09/2019	7	21/06/2019	7	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
40	17/LO/0372	220433	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation	Range Agreed	1	3	Not Available / Not Agreed			07/05/2019	3	Recruitment Finished
41	17/LO/1930	235819	A randomized, controlled, open-label, multiple ascending dose study of intravenous brincidofovir in adult allogeneic hematopoietic cell transplant recipients with adenovirus viremia	Range Agreed	1	2	Date Agreed	30/09/2019	0	09/05/2019	0	Withdrawn By Sponsor
42	17/NE/0124	216591	A randomised, double-blind, controlled, parallel-group, multi-country study to investigate the effect of a partially hydrolysed infant formula with added synbiotics on gut microbiota composition and clinical effectiveness in infants at high risk of d	Range Agreed	1	3	Date Agreed	28/02/2019	1	28/02/2019	1	Recruitment Finished
43	17/NI/0096	225743	HOPE-1 (HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS)	Range Agreed	2	4	Date Agreed	10/11/2018	0	01/04/2019	3	Withdrawn By Host
44	17/NW/0209	213231	An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy ofneoGAA (GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrateclinical decline or sub-optim	Range Agreed	1	3	Date Agreed	31/10/2018	0	19/04/2019	1	Recruitment Finished
45	17/SC/0462	228889	A Randomized, Double-blind Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-Seropositive Toddlers 12 to 24 Months of Age	Number Agreed	4	4	Date Agreed	31/03/2018	0	14/06/2019	4	Recruitment Finished
46	17/SW/0221	232448	A randomized, partially-blinded, active-controlled,multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy	Number Agreed	4	4	Date Agreed	03/11/2021	0	16/05/2019	0	Withdrawn By Sponsor
47	18/NE/0221	249183	A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPSII)	Range Agreed	1	4	Date Agreed	31/08/2019	0	25/04/2019	0	Withdrawn By Sponsor
48	18/SW/0162	248769	A prospective follow up study to assess performance, safety and efficacy of the PICO 7 NPWT system for surgically closed incision sites and skin grafts	Range Agreed	5	8	Date Agreed	29/03/2019	9	21/05/2019	9	Recruitment Finished
49	15/NE/0278	183395	An open-label, randomized, active-controlled,parallel-group, Phase-3b study of theefficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injectionsusing two different treatment regimens to subjects withneovascular age-related ma	Number Agreed	5	5	Date Agreed	43585	9	28/02/2019	9	Recruitment Finished